Cerliponase Alfa: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Cerliponase Alfa. Educational only — not medical advice.
Labeled uses
BRINEURA is indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
Source: FDA labeling via NIH DailyMed (set 485ab3c5…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.